Peptides: Legal Status Overview

The regulatory landscape for peptides is not binary — it exists across three distinct tiers, each with different legal implications for possession, prescribing, compounding, and athletic use.

The Three Regulatory Tiers

Tier 1: FDA-Approved Pharmaceuticals — These are peptides that have successfully completed clinical trials, received FDA approval, and are available by prescription only. They include tesamorelin (Egrifta — FDA-approved for HIV-associated lipodystrophy), semaglutide (Ozempic/Wegovy — diabetes and obesity), sermorelin (approved and off-label use), and oxytocin. Prescription required; dispensed through licensed pharmacies. Highest quality and regulatory oversight.

Tier 2: Compounding-Banned / Category 2 Substances — The FDA maintains a list of bulk drug substances nominated for use in compounding. “Category 2” substances are those the FDA has determined should NOT be used in compounded preparations — typically because there are safety concerns or insufficient evidence that the substance is safe for use in compounding. BPC-157 was placed on this list in 2023. This means licensed 503A and 503B compounding pharmacies cannot include it in formulations, even with a valid prescription.

Tier 3: Research Chemicals / Unscheduled — Most performance and research peptides (ipamorelin, CJC-1295, GHRP-2, TB-500, selank, semax, epitalon, GHK-Cu) are not scheduled under the Controlled Substances Act and not FDA-approved. They exist in a regulatory gray area: not illegal to possess, but labeled “not for human use” and cannot be marketed for human use.

Regulatory Category Summary

Regulatory Category	USA Status	Sports Prohibition	Import/Possession Risk	Examples
FDA-approved pharmaceutical	Prescription required; legal with Rx	Some prohibited (e.g., GH itself)	Legal with valid Rx; controlled import	Semaglutide, tesamorelin, sermorelin
Compounding-banned (Category 2)	Cannot be compounded; no valid Rx pathway	Varies by peptide	Gray-market purchase; no legal supply	BPC-157 (since 2023)
Research chemical (unscheduled)	Not controlled; “research use only”	WADA-prohibited GH peptides	Legal possession in most US jurisdictions; import risk varies	Ipamorelin, CJC-1295, TB-500, selank

Sports Anti-Doping: WADA S2 List

The World Anti-Doping Agency’s Section S2 (“Peptide Hormones, Growth Factors, Related Substances and Mimetics”) prohibits all GH-releasing peptides and analogs — including ipamorelin, CJC-1295, GHRP-2, GHRP-6, hexarelin, sermorelin, and any “substance with a similar chemical structure or similar biological effect.” This prohibition applies in-competition AND out-of-competition for substances that stimulate growth hormone. USADA enforces this in the USA.

Athletes subject to WADA-code testing who use research peptides face sanctions regardless of the peptide’s legal status under domestic law. Legality under the CSA does not confer sports-eligibility.

Australia: A Different Framework

Unlike the USA, Australia’s Therapeutic Goods Administration (TGA) schedules most performance peptides as Schedule 4 (Prescription Only Medicines). Importing Schedule 4 substances without a valid prescription or import permit can result in seizure by Australian Border Force and potential legal consequences. The Australian Sports Anti-Doping Authority (ASADA) follows WADA code. This makes Australia’s peptide regulatory environment significantly more restrictive than the USA.